ZOM - 1 Number That Might Send Investors Running From Zomedica's Stock
An up-and-coming business like Zomedica (NYSEMKT: ZOM) that is still in its early growth stages is naturally a riskier stock to buy than that of more established companies. It could be years before the business turns a profit, and its investors know they are taking a big chance. But if Zomedica's Truforma system, which veterinarians use to run diagnostics on animals, proves to be a hit, early investors could rake in huge gains.
Growing the business could take time. Managing expenses and minimizing losses will be crucial to keep the stock from falling, especially when the company isn't making money. But Zomedica's aggressive sales strategy could be doing it a disservice based on recent results. A major problem with this small-cap stock can be summarized with just one number...
Image source: Getty Images.
For further details see:
1 Number That Might Send Investors Running From Zomedica's Stock